Meeting Location: 
Cedars-Sinai Medical Center
Harvey Morse Conference Center
South Tower, Plaza Level
8700 Gracie Allen Drive
Los Angeles, CA 90048

Parking:
Self parking is available in the visitor parking lots P1, P2 or P4 for a daily rate of $10.00.

P1 on George Burns Road, North Tower, between Beverly Blvd and Alden Drive
P2 on George Burns Road, Spielberg Building, between Beverly Blvd and Alden Drive
P4 on Sherbourne Drive between 3rd St & Gracie Allen

Cardiovascular disease (CVD) was once thought of as primarily affecting men, but today, CVD is the number one killer of women in the US, claiming almost 400,000 American women every year. Furthermore, as the average age of the American woman increases, the morbidity and mortality rates of CVD are likely to increase dramatically. Yet, many women at risk for coronary heart disease are often not referred for appropriate diagnostic testing, perhaps because until recently, it was thought that the clinical manifestations of women with cardiovascular disease were essentially similar to those of men and warranted similar management. This means the disease process resulting in a heart attack or stroke may not be detected in women until later, with more serious consequences. Despite significant advances in our knowledge about preventive interventions, cardiovascular disease remains the leading killer of women in the United States. In an effort to further educate in this area our planning committee has assembled a distinguished faculty of national speakers, each with a unique expertise in the field of cardiovascular health and heart disease.

This in depth educational symposium will explore gender specific issues in coronary microvascular dysfunction, hormone therapy, cardiac resynchronization therapy, and updates in research and health policy. The purpose of this conference is to close the knowledge gap of physicians and allied health care professionals regarding sexspecific differences in cardiovascular disease, the impact these differences have on treatment options, and to highlight the importance of identifying women at risk for cardiovascular disease by utilizing the most current evidence-based treatment strategies for improved patient outcomes.

1. Examine the improvement of medical product development, product safety and efficacy in women from a regulatory perspective
2. Discuss how to advise women on reproductive hormone therapy and cardiac risk
3. Relate the benefits of referring women with heart disease to a cardiac rehabilitation program
4. Review and understand impact of supplements and fish oil on cholesterol
5. Analyze the benefits of using cardiac resynchronization therapy in women with heart failure with preserved ejection fraction
6. Describe anatomical valve disease amenable to percutaneous therapies
7. Assess the risks and benefits of percutaneous therapies
8. Describe how clinical manifestations of cardiovascular disease vary in women
9. Evaluate appropriate diagnostic testing for coronary microvascular dysfunction in women with chest pain who do not have obstructive coronary artery disease
10. Define the role of specialized care teams focused on Women’s Heart Health and Disease
11. Explore case examples of hormone, stress, cholesterol, hypertension and CMD management and interventions
12. Focus clinical practice approach on the unique aspects of cardiovascular care for women to provide necessary resources for prevention, diagnosis and treatment of CVD in women

Received by 4/28/2018

Received after 4/28/2018

Cedars-Sinai Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Cedars-Sinai Medical Center designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

To exhibit at the upcoming conference, please contact cme@cshs.org